Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Atezolizumab + Cabozantinib Postpones mCRPC Progression.

2.

Breast cancer patients' arms swell less after an effective lymph node transfer.

3.

Citing a cancer risk, the EPA sets a new limit on medical sterilization chemicals.

4.

Cancer Diagnoses Slow to Recover From Effects of COVID Pandemic

5.

Relationship-building key to addressing oncologist shortages in rural care


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot